Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MELPHALAN

All products: general benefit

Other products in the same Health Canada class (L01A, L01AA) — coverage varies; not interchangeable

  • Chlorambucil (Leukeran): general benefit
  • Cyclophosphamide (Procytox): general benefit, Not a benefit
  • Busulfan (Myleran): general benefit
  • Lomustine ccnu (Gleostine): general benefit, Listing status unconfirmed
  • Temozolomide (Temodal): general benefit

Alkeran · DIN 00004715 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Alkeran · DIN 00004715 Manufacturer: Aspen Pharma Trading Limited; listing date 1996-10-01 Health Canada: Marketed since 2018-04-26 · brand ALKERAN · ATC L01AA03 MELPHALAN · form Tablet · route Oral · ingredients MELPHALAN 2 MG · company Aspen pharmacare canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Alkeran: Formulary list price $2.5318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.5318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1195 · Verify on the e-Formulary ↗ (DIN 00004715)

Source record
DIN 00004715: Alkeran Raw flags: sec3=Y Item: 100000017; group id 173; item number 0305; lccId None; manufacturer id ASN Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $2.5318; ministry $2.5318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00004715 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1195
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00004715
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

LOMUSTINE (CCNU)

· 5 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (1) · strengths: 10mg, 40mg, 100mg · Cap

TEMOZOLOMIDE

· 20 products · General benefit · strengths: 5mg, 20mg, 100mg, 140mg, 250mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: multiple myeloma
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. POMALIDOMIDE · Off-Formulary Interchangeable, not an ODB benefit 1 Indications POMALYST® (pomalidomide) is indicated: • in combination with dexamethasone (dex) and bortezomib for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior treatment regimen that included lenalidomide. PM: https://pdf.hres.ca/dpd_pm/00081218.PDF; date 2025-07-28; DIN 02419580; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ALKERAN® (melphalan) is indicated for: • the palliative treatment of multiple myeloma • the palliation of nonresectable epithelial carcinoma of the ovary. • ALKERAN® for injection has been administered by hyperthermic isolated limb perfusion as an adjuvant to surgery in the treatment of malignant melanoma. However, there have been no prospective controlled or uncontrolled trials evaluating dose and its relationship to disease response and/or toxicity. 1.1 Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years): ALKERAN is approved for use in the geriatric population. However, dosing precautions apply (see 4.2 Recommended Dose and Dosage Adjustment and 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00076418.PDF PM date: DEC 31, 1964 Source product: ALKERAN; DIN 00004715; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.